Pricing of HPV Vaccines in Europe: Back to the Future?
- 23 February 2018
- journal article
- editorial
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 16 (3) , 275-277
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Confirming cross-protection of bivalent HPV vaccineThe Lancet Infectious Diseases, 2017
- Competition in pharmaceuticals: more product- than price-oriented?The European Journal of Health Economics, 2017
- Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysisVaccine, 2017
- Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the NetherlandsThe Journal of Infectious Diseases, 2017
- Vaccination planning in Italy: increasing vaccines while reducing coverage?Expert Review of Pharmacoeconomics & Outcomes Research, 2016
- Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysisThe Lancet Global Health, 2016
- Long-term modeling on HPV vaccination: do we really need any more?Expert Review of Pharmacoeconomics & Outcomes Research, 2015
- Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccinesJournal of the Royal Society of Medicine, 2014
- HPV Vaccination for Boys? Talking Economic SenseThe Journal of Sexual Medicine, 2012
- Pricing Human Papillomavirus VaccinesPharmacoEconomics, 2012